Back Hepatitis B

Hepatitis B

May Is Hepatitis Awareness Month

May is Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of viral hepatitis and to encourage more people to get tested and receive care for hepatitis B and C. Hepatitis Testing Day is coming up on May 19.

alt

Read more:

EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B

Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.

alt

Read more:

EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment

Dramatic regional differences in survival rates for people with hepatocellular carcinoma (HCC) are largely attributable to varying national policies regarding screening and treatment, according to study findings presented at the 49thEASL International Liver Congress last week in London. Related research showed that percutaneous radiofrequency ablation is effective for treating single liver cancer tumors.

alt

Read more:

EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission

An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the EASL International Liver Congress this month in London.

alt

Read more:

EASL 2014: International Liver Congress Starts this Week in London

The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.

alt

Read more:

EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse

Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.

 

alt

Read more:

U.S. Government Releases Updated Viral Hepatitis Action Plan

On April 3 the federal government released its latest 3-year update to the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (initially launched in 2011), which provides a framework for strengthening the nation's response to hepatitis B and C.

alt

Read more:

EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients

Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in HBeAg positive chronic hepatitis B patients, as did added interferon after long-term nucleoside therapy, but adding interferon after a only short course of antivirals did not improve response, according to a set of studies presented at the 49th EASL International Liver Congress last week in London.

alt

Read more:

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more: